A phase I study to investigate the pharmacokinetics, safety and tolerability of topical applied 0.25% solution of SM04554 in male subjects with androgenetic alopecia
Latest Information Update: 24 Feb 2022
At a glance
- Drugs Dalosirvat (Primary)
- Indications Alopecia
- Focus Pharmacokinetics
Most Recent Events
- 16 May 2016 Status changed from recruiting to completed.
- 25 Sep 2015 New trial record